NextFin News - Eli Lilly on Thursday reported that its next-generation obesity treatment, retatrutide, achieved a record-breaking 28.3% average weight loss in a pivotal Phase 3 clinical trial. The results, which Dan Skovronsky, Lilly’s chief scientific and product officer, described as "making history," position the drug as a potential pharmacological alternative to bariatric surgery. The trial involved 2,500 patients and demonstrated that nearly half of the participants on the highest dose lost at least 30% of their body weight over an 80-week period.
The drug, colloquially known as the "triple G" for its ability to target three distinct gut hormones—GLP-1, GIP, and glucagon—represents a significant technological leap over current market leaders. While Novo Nordisk’s Wegovy targets only GLP-1 and Lilly’s own Zepbound targets two hormones, retatrutide’s triple-action mechanism appears to accelerate metabolic expenditure while simultaneously suppressing appetite. In an extension of the study focusing on patients with a BMI of 35 or higher, weight loss reached 30.3% over 104 weeks, a threshold previously thought unattainable through medication alone.
The commercial implications are substantial as Lilly seeks to defend its 60.1% share of the U.S. obesity and diabetes market. Analysts at TD Cowen, who have maintained a generally bullish outlook on the sector's growth, estimated in January that retatrutide could generate $3.8 billion in annual sales by 2030. This projection aligns with broader industry expectations that the total obesity drug market could exceed $100 billion within the next decade. However, the TD Cowen estimate remains a single-institution forecast and may not account for potential pricing pressures or the entry of cheaper biosimilars later in the decade.
Despite the efficacy, the trial highlighted the physiological toll of such rapid weight loss. Gastrointestinal side effects remained prevalent, with 42% of patients on the highest dose reporting nausea and roughly 32% experiencing diarrhea. More notably, 12% of participants reported dysesthesia—an unpleasant nerve sensation—and 8% developed urinary tract infections. Skovronsky suggested these issues might be linked to the "velocity of weight loss" rather than the drug's direct toxicity, noting that similar patterns are observed in surgical patients. Discontinuation rates at the highest dose reached 11.3%, suggesting that the drug's potency may be a double-edged sword for long-term adherence.
Lilly’s strategy appears to involve a tiered approach to mitigate these tolerability issues. The trial also tested a lower 4-milligram dose, which yielded a 19% weight loss with a discontinuation rate of just 4%—actually lower than the placebo group’s 5%. This "low-dose, high-tolerability" profile could allow Lilly to capture a broader patient demographic that does not require or cannot tolerate the extreme weight loss associated with the maximum dosage. By offering a spectrum of efficacy, the company aims to lock in patients who might otherwise churn due to side effects.
The competitive landscape is tightening as Novo Nordisk attempts to bridge the gap. In March 2025, Novo committed up to $2 billion to acquire a triple-hormone candidate from United Laboratories International, a Chinese pharmaceutical firm. While Novo’s acquisition confirms the industry's shift toward triple-agonist therapies, that drug remains in early-stage development. For now, Lilly’s successful Phase 3 data gives it a multi-year lead in the race to define the next standard of care in metabolic medicine.
Explore more exclusive insights at nextfin.ai.
